Emcure gets CDSCO nod for Poviztra MASH indication
Analysis based on 9 articles · First reported Jul 20, 2026 · Last updated Jul 20, 2026
The approval expands Emcure's addressable market for Poviztra into the liver disease segment, potentially boosting revenues. It also strengthens Novo Nordisk's presence in India's metabolic disease market.
Emcure Pharmaceuticals announced that its obesity drug Poviztra (semaglutide) has received approval from the India — Central Drugs Standard Control Organisation (CDSCO) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. This makes semaglutide the first and only GLP-1 receptor agonist approved in India for this indication. The approval is based on results from the global Phase III ESSENCE trial, which showed resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37% of patients. Poviztra, manufactured and imported from Novo Nordisk's European facility, already has approved indications for chronic weight management, obesity-related cardiovascular disease, and adolescent obesity. The new indication expands Emcure's portfolio for treating metabolic diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard